Document is current

Article History

Received: 17 January 2025

Accepted: 25 April 2025

First Online: 15 May 2025

Declarations

:

: The patient-level data included in this study were evaluated and approved by the Institutional Review Board or Independent Ethics Committee, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines.

: All participants provided informed consent prior to enrolling in the clinical trials included in this study; due to the de-identified nature of the PINC AI™ database, consent was not required for these patients.

: Miguel Giovanni Uriol-Rivera is a consultant of Alexion, AstraZeneca Rare Disease, including expert testimony fees; a receipt of honoraria from Alexion, AstraZeneca Rare Disease, has participated in advisory boards for Alexion, AstraZeneca Rare Disease and has also received honoraria from GlaxoSmithKline. Frank R Ernst was an employee of CTI Clinical Trial and Consulting Services, Inc, who were contracted by Alexion, AstraZeneca Rare Disease, at the time of the study. John N Booth III was an employee of CTI Clinical Trial and Consulting Services, Inc, who were contracted by Alexion, AstraZeneca Rare Disease to conduct the current study, at the time of the study. Àngels Comas is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Christoph Gasteyger is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Ioannis Tomazos was an employee of Alexion, AstraZeneca Rare Disease at the time this study was conducted. Ching Lum was an employee of Alexion, AstraZeneca Rare Disease at the time this study was conducted. Yan Wang is a current employee and stakeholder of Alexion, AstraZeneca Rare Disease. Ana I Ávila has received honoraria from, and participated in advisory boards for Alexion, AstraZeneca Rare Disease, and is a recipient of honoraria from GlaxoSmithKline.